COR588 is our second generation molecule. Like our lead molecule COR388 or atuzaginstat, it is also a lysine-gingipain inhibitor. So, it works by the same mechanism. It has a longer half-life, so we believe, at this point, that it will be based on data particularly from this first human study, that it will be a once-a-day drug. It has a cleaner profile overall in all the tox studies. And it’s in a single and multiple ascending dose study, that we described the single doses were at 25, 50, 100 and 200 milligrams, each single dose...
COR588 is our second generation molecule. Like our lead molecule COR388 or atuzaginstat, it is also a lysine-gingipain inhibitor. So, it works by the same mechanism. It has a longer half-life, so we believe, at this point, that it will be based on data particularly from this first human study, that it will be a once-a-day drug. It has a cleaner profile overall in all the tox studies. And it’s in a single and multiple ascending dose study, that we described the single doses were at 25, 50, 100 and 200 milligrams, each single dose. The multiple ascending dose will study it for 10 days, once-a-day dosing. And, like most Phase I studies, there are no efficacy outcomes, just safety and PK.
And, so far, the safety has been very, very clean, as expected. Really nothing that’s clinically significant on any of the safety measures. And the PK has been well behaved. It’s a little more than linear within the dose range studied so far. As I said, the lead molecule had about a five hour half-life. This one’s more like 10 or 12. And, because of the irreversible mechanism, we think it will be fine to dose it as a once-a-day drug, as opposed to twice-a-day on the lead molecule.
So, that’s a quick update about the second generation COR588 molecule.
